Literature DB >> 14587047

High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors.

Emmanuelle de Raucourt1, Christophe Barbier, Patrick Sinda, Mamoun Dib, Jean-Yves Peltier, Catherine Ternisien.   

Abstract

We report two patients who developed acquired factor V (FV) inhibitors not related to exposure to bovine thrombin. Associated conditions were found in one patient (surgery, antibiotic administration) but none in the other one. Bleeding complications occurred only in the patient with idiopathic FV inhibitor, leading to packed red cell infusion. Laboratory findings showed the presence of specific FV inhibitors with titers of 5.5 and 5 Bethesda units, respectively. These two patients received high-dose intravenous immunoglobulin and FV levels normalized within a few days with a concomitant disappearance of FV inhibitors. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14587047     DOI: 10.1002/ajh.10420

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Isolated factor V deficiency in a patient with elevated PT and aPTT during routine pre-operative laboratory screening.

Authors:  Keyur Thakar; Kaushal Parikh; Yamei Chen; Delong Liu
Journal:  Stem Cell Investig       Date:  2014-02-08

3.  Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature.

Authors:  Qing-ya Cui; Hong-shi Shen; Tian-qin Wu; Hai-fei Chen; Zi-qiang Yu; Zhao-yue Wang
Journal:  Drug Des Devel Ther       Date:  2015-04-24       Impact factor: 4.162

4.  Acquired Inhibitors to Multiple Coagulation Factors (V, IX, and XII) Identified in a Unique Patient with Hepatocellular Carcinoma.

Authors:  Osamu Imataki; Takeshi Arai; Makiko Uemura
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.